Recurrent genomic rearrangements in primary testicular lymphoma

Journal of Pathology

Volumn 236, Issue 2, 2015, Pages 136-141

  Twa, David D W ^a,b   Mottok, Anja ^a,b   Chan, Fong Chun ^a,c   Ben Neriah, Susana ^a   Woolcock, Bruce W ^a   Tan, King L ^a   Mungall, Andrew J ^a   McDonald, Helen ^d   Zhao, Yongjun ^d   Lim, Raymond S ^a   Nelson, Brad H ^c,d   Milne, Katy ^d   Shah, Sohrab P ^a   Morin, Ryan D ^a,e   Marra, Marco A ^a,d   Scott, David W ^a   Gascoyne, Randy D ^a,b   Steidl, Christian ^a,b  

^a BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d BRITISH COLUMBIA CANCER AGENCY   (Canada)

^e SIMON FRASER UNIVERSITY   (Canada)

Author keywords

capture sequencing; CD274; CIITA; fluorescence in situ hybridization (FISH); FOXP1; genomic rearrangements; PDCD1LG2; primary testicular lymphoma (PTL); programmed death ligands

Indexed keywords

BRM PROTEIN; FORMALDEHYDE; PARAFFIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXP1; UNCLASSIFIED DRUG; CD274 PROTEIN, HUMAN; FORKHEAD TRANSCRIPTION FACTOR; FOXP1 PROTEIN, HUMAN; MHC CLASS II TRANSACTIVATOR PROTEIN; NUCLEAR PROTEIN; PDCD1LG2 PROTEIN, HUMAN; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2; REPRESSOR PROTEIN; TRANSACTIVATOR PROTEIN;

ARTICLE; B CELL LYMPHOMA; BACTERIAL ARTIFICIAL CHROMOSOME; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE REARRANGEMENT; GENOMICS; IMMUNOHISTOCHEMISTRY; INTRON; LARGE CELL LYMPHOMA; PRIMARY TESTICULAR DIFFUSE LARGE B CELL LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TESTIS CANCER; CHROMOSOME BREAKAGE; GENE DELETION; GENE TRANSLOCATION; GENETICS; HUMAN; MALE; RECURRENT DISEASE; TESTIS TUMOR;

ANTIGENS, CD274; CHROMOSOME BREAKPOINTS; CHROMOSOMES, ARTIFICIAL, BACTERIAL; FORKHEAD TRANSCRIPTION FACTORS; GENE DELETION; GENE REARRANGEMENT, B-LYMPHOCYTE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; NUCLEAR PROTEINS; PROGRAMMED CELL DEATH 1 LIGAND 2 PROTEIN; RECURRENCE; REPRESSOR PROTEINS; TESTICULAR NEOPLASMS; TRANS-ACTIVATORS; TRANSLOCATION, GENETIC;

EID: 84929294482     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4522     Document Type: Article

References (20)

1. Cheah CY, Wirth A, Seymour JF,. Primary testicular lymphoma. Blood 2014; 123: 486-493.
2. Bernasconi B, Uccella S, Martin V, et al., Gene translocations in testicular lymphomas. Leuk Lymphoma 2014; 55: 1410-1412.
3. Booman M, Szuhai K, Rosenwald A, et al., Genomic alterations and gene expression in primary diffuse large B cell lymphomas of immune-privileged sites: the importance of apoptosis and immunomodulatory pathways. J Pathol 2008; 216: 209-217.
4. Jordanova ES, Riemersma SA, Philippo K, et al., β2-microglobulin aberrations in diffuse large B-cell lymphoma of the testis and the central nervous system. Int J Cancer 2003; 103: 393-398.
5. Kraan W, van Keimpema M, Horlings HM, et al., High prevalence of oncogenic MYD88 and CD79B mutations in primary testicular diffuse large B-cell lymphoma. Leukemia 2014; 28: 719-720.
6. Kuper-Hommel MJ, Schreuder MI, Gemmink AH, et al., T(14;18)(q32;q21) involving MALT1 and IGH genes occurs in extranodal diffuse large B-cell lymphomas of the breast and testis. Mod Pathol 2013; 26: 421-427.
7. Riemersma SA, Oudejans JJ, Vonk MJ, et al., High numbers of tumour-infiltrating activated cytotoxic T lymphocytes, and frequent loss of HLA class I and II expression, are features of aggressive B cell lymphomas of the brain and testis. J Pathol 2005; 206: 328-336.
8. Villa D, Connors JM, Shenkier TN, et al., Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy. Ann Oncol 2010; 21: 1046-1052.
9. Twa DD, Chan FC, Ben-Neriah S, et al., Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma. Blood 2014; 123: 2062-2065.
10. Scott DW, Mungall KL, Ben-Neriah S, et al., TBL1XR1/TP63: a novel recurrent gene fusion in B-cell non-Hodgkin lymphoma. Blood 2012; 119: 4949-4952.
11. Morin RD, Mendez-Lago M, Mungall AJ, et al., Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 2011; 476: 298-303.
12. McPherson A, Wu C, Wyatt AW, et al., nFuse: discovery of complex genomic rearrangements in cancer using high-throughput sequencing. Genome Res 2012; 22: 2250-2261.
13. Steidl C, Shah SP, Woolcock BW, et al., MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature 2011; 471: 377-381.
14. Gunawardana J, Chan FC, Telenius A, et al., Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma. Nat Genet 2014; 46: 329-335.
15. Jia D, Dong R, Jing Y, et al., Exome sequencing of hepatoblastoma reveals novel mutations and cancer genes in the Wnt pathway and ubiquitin ligase complex. Hepatology 2014; 60: 1686-1696.
16. Pasqualucci L, Migliazza A, Basso K, et al., Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma. Blood 2003; 101: 2914-2923.
17. van Keimpema M, Gruneberg LJ, Mokry M, et al., FOXP1 directly represses transcription of proapoptotic genes and cooperates with NF-κB to promote survival of human B cells. Blood 2014; 124: 3431-3440.
18. Haralambieva E, Adam P, Ventura R, et al., Genetic rearrangement of FOXP1 is predominantly detected in a subset of diffuse large B-cell lymphomas with extranodal presentation. Leukemia 2006; 20: 1300-1303.
19. Rouhigharabaei L, Finalet Ferreiro J, Tousseyn T, et al., Non-IG aberrations of FOXP1 in B-cell malignancies lead to an aberrant expression of N-truncated isoforms of FOXP1. PLoS One 2014; 9: e85851.
20. Ansell SM, Lesokhin AM, Borrello I, et al., PD-1 Blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2014; 372: 311-319.